SiBone $SIBN Shares Purchased by American Century Companies Inc.

Key Points

• American Century Companies Inc. increased its stake in SiBone by 11.1%, now owning approximately 2,642,322 shares valued at $37 million.
• Other institutional investors have also significantly increased their stakes, with Russell Investments Group Ltd. growing its position by 765.3% during the same quarter.
• SiBone reported better-than-expected earnings, with a revenue of $48.63 million, surpassing analysts' estimates, and currently holds a consensus rating of "Buy" among analysts.

American Century Companies Inc. increased its stake in shares of SiBone (NASDAQ:SIBN - Free Report) by 11.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,642,322 shares of the company's stock after purchasing an additional 264,254 shares during the quarter. American Century Companies Inc. owned 6.20% of SiBone worth $37,072,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SIBN. ANTIPODES PARTNERS Ltd acquired a new position in SiBone during the 1st quarter worth $34,000. Virtus Fund Advisers LLC purchased a new stake in SiBone during the 4th quarter worth about $40,000. GAMMA Investing LLC lifted its holdings in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after buying an additional 3,867 shares during the last quarter. Johnson Investment Counsel Inc. purchased a new stake in SiBone during the 1st quarter worth about $148,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in SiBone during the 1st quarter worth about $162,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SIBN has been the subject of a number of recent analyst reports. Truist Financial lifted their price target on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Cantor Fitzgerald set a $25.00 price target on SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th. Finally, Wall Street Zen cut SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, SiBone currently has a consensus rating of "Buy" and a consensus target price of $23.67.

SiBone Stock Performance

Shares of SIBN traded up $0.75 during midday trading on Friday, reaching $16.39. 333,628 shares of the stock were exchanged, compared to its average volume of 509,321. The business's 50-day moving average price is $17.06 and its 200 day moving average price is $16.52. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a market capitalization of $707.06 million, a price-to-earnings ratio of -29.27 and a beta of 0.91.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%.The firm had revenue of $48.63 million for the quarter, compared to analyst estimates of $48.12 million. SiBone has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,833 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total transaction of $59,871.46. Following the transaction, the insider owned 275,288 shares of the company's stock, valued at $4,299,998.56. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Laura Francis sold 11,343 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.60, for a total value of $176,950.80. Following the transaction, the chief executive officer directly owned 419,704 shares in the company, valued at approximately $6,547,382.40. This represents a 2.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,967 shares of company stock valued at $829,469. Insiders own 4.00% of the company's stock.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.